Hedge Fund's Novel AIA Strategy Targets Acorda's MS Drug

Law360, New York (February 11, 2015, 5:14 PM EST) -- An organization tied to hedge fund manager Kyle Bass on Tuesday filed a petition for review under the America Invents Act of the patent for Acorda Therapeutics Inc.’s multiple sclerosis drug Ampyra, arguing that a previous invention and publications invalidate the patent as obvious.

The Coalition for Affordable Drugs (ADROCA) LLC, which is affiliated with Hayman Credes Master Fund LP, asked the Patent Trial and Appeal Board to find that the patent for Ampyra unpatentable as obvious in view of prior art, such as an earlier patent for a treatment of neurological diseases such as MS and publications from a medical...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!